TLR2 and gout: Studies have shown that the absence of HDAC3 in macrophages alleviates MSU crystal-induced gout inflammation by inhibiting the TLR2/4-driven IL-6/STAT3 signaling pathway, suggesting that HDAC3 may serve as a potential therapeutic target for gout (Yang et al., 2024).